{"id":395889,"date":"2020-12-08T16:33:09","date_gmt":"2020-12-08T21:33:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=395889"},"modified":"2020-12-08T16:33:09","modified_gmt":"2020-12-08T21:33:09","slug":"cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/","title":{"rendered":"Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris"},"content":{"rendered":"
\n

\n First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T <\/em>
\n technology<\/em>
\n beyond cancer into autoimmune diseases<\/em>\n <\/p>\n

PHILADELPHIA, Dec. 08, 2020 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the first patient has been dosed in the DesCAARTes\u2122 Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV).<\/p>\n

\u201cThis is an important milestone in the development of our lead product candidate, DSG3-CAART, for patients with mucosal pemphigus vulgaris and for patients with B cell mediated autoimmune diseases more generally. We believe this is the first time a highly targeted, antigen specific cell therapy has been dosed in a patient with autoimmune disease. The study is designed to provide insights into the clinical effect of our precision CAAR T cell therapy in patients suffering from mPV,\u201d said David J. Chang, M.D., Chief Medical Officer of Cabaletta Bio. \u201cCurrently available therapies for mPV patients, including steroids, typically induce broad immunosuppression, offer modest efficacy and\/or are associated with frequent relapses. DSG3-CAART therapy, which is engineered to target and specifically eliminate the cells responsible for generating disease-causing autoantibodies while preserving the healthy immune system, provides mPV patients the potential of a deep and durable response, perhaps even a cure.\u201d<\/p>\n

\u201cThis is a huge accomplishment that will advance the entire field of cell therapy,\u201d stated Carl H. June, M.D., who is a member of the Cabaletta Bio Scientific Advisory Board and the Richard W. Vague Professor of Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania, \u201cThe precise CAAR T technology which was discovered at Penn and is being developed by Cabaletta Bio builds on the legacy of commercially-approved CAR T therapies, to offer the promise of deep and durable responses beyond oncology to patients with autoimmune diseases.\u201d<\/p>\n

\n About the <\/strong>
\n DesCAARTes<\/strong>
\n \u2122 Clinical Trial<\/strong>
\n
Cabaletta Bio\u2019s DesCAARTes\u2122 Phase 1 trial is an open-label, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV). The trial is designed to evaluate the safety and tolerability of DSG3-CAART as well as to identify evidence of target engagement and early signs of efficacy. The study consists of three parts: 1) dose escalation, 2) dose consolidation, and 3) expansion at the final selected dose and schedule. The trial is expected to enroll approximately 30 subjects across multiple clinical sites throughout the United States. Visit clinicaltrials.gov (NCT04422912<\/a>) for more information. <\/p>\n

\n About Pemphigus Vulgaris<\/strong>
\n
PV is a rare autoimmune blistering disease that is characterized by the loss of adhesion between cells of the skin or mucous membranes. PV is caused by the production of autoantibodies that disrupt structural proteins within the skin and\/or mucosa that connect with other proteins to enable the skin and\/or mucosal cells to connect with each other. The autoantibodies can target DSG3 and\/or desmoglein 1 (DSG1), which are primarily expressed in the mucosal membranes and skin, respectively. mPV is characterized by autoantibodies against DSG3 only whereas mucocutaneous PV (mcPV) is characterized by autoantibodies against DSG3 and DSG1.<\/p>\n

\n About CAAR T Cell Therapy<\/strong>
\n
Chimeric AutoAntibody Receptor (CAAR) T cells are designed to selectively bind and eliminate only disease-causing B cells, while sparing the normal B cells that are essential for human health. CAAR T cells are based on the chimeric antigen receptor (CAR) T cell technology. While CAR T cells typically contain a CD19-targeting molecule, CAAR T cells express an autoantibody-targeted antigen on their surface. The co-stimulatory domain and the signaling domain of both a CAR T cell and a CAAR T cell carry out the same activation and cytotoxic functions. Thus, Cabaletta Bio\u2019s CAARs are designed to direct the patient\u2019s T cells to kill only the pathogenic cells that express disease-causing autoantibodies on their surface, potentially leading to complete and durable remission of disease while sparing all other B cell populations that provide beneficial immunity from infection.<\/p>\n

About Cabaletta Bio<\/strong>
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta\u2019s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company\u2019s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes\u2122\u00a0phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov<\/a>. The Company\u2019s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains \u201cforward-looking statements\u201d of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding expectations regarding the progress and results of its DesCAARTes\u2122 Phase 1 trial, including Cabaletta Bio\u2019s ability to enroll the requisite number of patients and dosing of its first patient; the expectation that Cabaletta Bio may improve outcomes for patients suffering from mPV; the effectiveness and timing of product candidates that Cabaletta may develop, including in collaboration with academic partners; the safety, efficacy and tolerability of DSG3-CAART for the treatment of mPV; the impact of preclinical data on the future development of CAAR T therapies in our pipeline portfolio expectations of the potential impact of COVID-19 on strategy, future operations, and the timing of its clinical trials, including the potential impacts on initiation of its DesCAARTes\u2122 Phase 1 trial; and statements regarding regulatory filings regarding its development programs.<\/p>\n

Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: Cabaletta Bio\u2019s ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its preclinical and clinical trials of DSG3-CAART; risks related to clinical trial site activation or enrollment rates that are lower than expected; risks related to unexpected safety or efficacy data observed during clinical studies; risks related to the impact of public health epidemics affecting countries or regions in which we have operations or do business, such as COVID-19; Cabaletta\u2019s ability to retain and recognize the intended incentives conferred by Orphan Drug Designation for DSG3-CAART for the treatment of PV and Fast Track Designation for DSG3-CAART for the treatment of mPV; risks related to Cabaletta\u2019s ability to protect and maintain its intellectual property position; uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta\u2019s actual results to differ from those contained in the forward-looking statements, see the section entitled \u201cRisk Factors\u201d in Cabaletta\u2019s most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta\u2019s other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law.<\/p>\n

\n Editor\u2019s Note: <\/em>
\n Dr. June <\/em>
\n is a University of Pennsylvania <\/em>
\n faculty member <\/em>
\n and holds an equity stake in the Company. <\/em>\n <\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

Anup Marda
Chief Financial Officer
investors@cabalettabio.com<\/a>\u00a0<\/p>\n

Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com<\/a>\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune diseases PHILADELPHIA, Dec. 08, 2020 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the first patient has been dosed in the DesCAARTes\u2122 Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV). \u201cThis is an important milestone in the development of our lead product candidate, DSG3-CAART, for patients with mucosal pemphigus vulgaris and for patients with B cell mediated autoimmune diseases … <\/p>\n

Continue reading “Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-395889","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune diseases PHILADELPHIA, Dec. 08, 2020 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the first patient has been dosed in the DesCAARTes\u2122 Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV). \u201cThis is an important milestone in the development of our lead product candidate, DSG3-CAART, for patients with mucosal pemphigus vulgaris and for patients with B cell mediated autoimmune diseases … Continue reading "Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-08T21:33:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODk1MiMzODYxNjgzIzIxMjUwMzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris\",\"datePublished\":\"2020-12-08T21:33:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/\"},\"wordCount\":1394,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODk1MiMzODYxNjgzIzIxMjUwMzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/\",\"name\":\"Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODk1MiMzODYxNjgzIzIxMjUwMzA=\",\"datePublished\":\"2020-12-08T21:33:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODk1MiMzODYxNjgzIzIxMjUwMzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODk1MiMzODYxNjgzIzIxMjUwMzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/","og_locale":"en_US","og_type":"article","og_title":"Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris - Market Newsdesk","og_description":"First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune diseases PHILADELPHIA, Dec. 08, 2020 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the first patient has been dosed in the DesCAARTes\u2122 Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV). \u201cThis is an important milestone in the development of our lead product candidate, DSG3-CAART, for patients with mucosal pemphigus vulgaris and for patients with B cell mediated autoimmune diseases … Continue reading \"Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-08T21:33:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODk1MiMzODYxNjgzIzIxMjUwMzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris","datePublished":"2020-12-08T21:33:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/"},"wordCount":1394,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODk1MiMzODYxNjgzIzIxMjUwMzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/","name":"Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODk1MiMzODYxNjgzIzIxMjUwMzA=","datePublished":"2020-12-08T21:33:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODk1MiMzODYxNjgzIzIxMjUwMzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODk1MiMzODYxNjgzIzIxMjUwMzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-announces-first-patient-dosed-in-landmark-descaartes-trial-of-dsg3-caart-for-treatment-of-mucosal-dominant-pemphigus-vulgaris\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes\u2122 Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=395889"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395889\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=395889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=395889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=395889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}